Announced Mon, 27 Jul, 2026 · 22:54 IST
Cipla gets US FDA approval for Generic Advair Diskus
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.2%1-day move
₹1415.00
prior close
₹1426.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+0.7+0.9+1.1+4.2+3.7+4.0+3.2+3.2+4.4+1.1+0.0-2.2—
Up moveDown movePending
AI summary
Cipla received US FDA approval for its generic version of Advair Diskus (fluticasone propionate and salmeterol) in all three strengths. The drug treats asthma and COPD. The US market for this product is around $908 million per IQVIA. This is Cipla's first dry powder inhaler approval from its US manufacturing facility. Launch is expected in Q2 of FY 2026-27.
Likely market impact
Opens access to a $908 million US market. Could boost revenue and margins from FY27. Positive for shareholders.